Answers are grounded in this paper and cite their sources.
In silico and in vitro analysis reveals ganoderic acid A interacts with MCT1 and MCT4, suggesting potential anticancer applications.
In recent years, the search for novel anticancer agents has increasingly focused on monocarboxylate transporters (MCTs) because of their involvement in tumor metabolism. Ganoderic acid A (GAA), a triterpenoid derived from the medicinal mushroom Ganoderma lucidum, has demonstrated anticancer potential; however, its interaction with MCT isoforms remains insufficiently characterized. In this study, we examined the interaction between GAA and MCT1 and MCT4 using complementary computational and experimental approaches. Full-length structures of MCT1 and MCT4 were predicted using AlphaFold2 and validated with the SAVES server. Molecular docking and molecular dynamics simulations using the known dual inhibitor syrosingopine as a reference indicated that GAA can associate with both MCT1 and MCT4. Cellular thermal shift assay (CETSA) and isothermal dose-response fingerprinting (ITDRF) showed that GAA thermally destabilized both MCT1 and MCT4, supporting a direct protein-compound interaction. Notably, ITDRF analysis revealed enhanced stability of a higher-molecular-weight MCT4, suggesting a biphasic binding behavior. Together, these findings indicate that GAA directly interacts with MCT1 and MCT4, and uncovers a biphasic binding pattern associated with MCT4.
No takes yet. Share an insight, caveat, or question.
Bashir et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: